|
|
|
Screening of potential therapeutic compounds for osteoporosis based on L1000 database |
LIANG Pengchen1,ZHOU Ziyan2,3, CHANG Qing2, YI Qingqing2, SUN Miaomiao2,3, TANG Yeling2,3, CAO Liou4,5, YANG Jie6 |
(1. School of Microelectronics,Shanghai University, Shanghai 201800; 2. Clinical Research Center, Jiading District Central Hospital Affiliated to Shanghai University of Medicine ＆ Health Sciences, Shanghai 201800; 3. Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 201203; 4. Department of Nephrology, Jiading District Central Hospital Affiliated to Shanghai University of Medicine ＆ Health Sciences, Shanghai 201800; 5. Department of Nephrology, Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University, Shanghai 200127; 6. GCP Office, Jiading District Central Hospital Affiliated to Shanghai University of Medicine ＆ Health Sciences, Shanghai 201800, China)
|
|
|
|
Abstract Objective:The L1000 micro-interference data set was used to screen compounds for the treatment of osteoporosis, and the evaluation and cytological activity verification by multiple biological information methods were conducted, aiming to discover new osteoporosis treatment drugs.Methods:The data related to osteoporosis（OP）were retrieved in the GEO（Gene Expression Omnibus）database, and the difference in gene expression levels on the datasets was analyzed using limma package in R language. Pathway enrichment analysis of differential genes was performed using MetaScape data platform. The resulting differential OP gene expression profiles were analyzed to match potential OP therapeutic compounds in the L1000 dataset of the Connectivity Map database. The molecular docking study of the matching compounds and bone metabolism targets was conducted by Autodock_Vina software, and the ADMET（absorption, distribution, metabolism, excretion, and toxicity）characteristics of the matching compounds were calculated and analyzed by using pkCSM database. The activity of the candidate compound was studied by a cell proliferative activity experiment.Results:After analyzing the dataset of osteoporosis expression profile, 195 differential genes related to osteoporosis were obtained, including 127 genes with significantly up-regulated expression and 68 genes with significantly downregulated expression. There were 146 GO Biological Processes with differential gene enrichment;There were nine enriched KEGG signaling pathways and nine enriched Reactome Gene Sets. A total of 10 potential therapeutic compounds were matched in the L1000 dataset: diethylstilbestrol, PLX-4720, mezlocillin, KU-C103428N, rhapontin, maravir, quinine, MST-312, risperidone, and CO-102862. Through molecular docking studies, we found that the matching compounds have multi-target characteristics, and the main docking activities with the compounds are CAⅡ, PGR, ERβ, BMP2 and other OP targets. The ADMET properties of potential therapeutic compounds were calculated using the ADMET calculation module of the pkCSM database, which showed that mezlocillin had good ADME performance and low toxicity, with good comprehensive evaluation. Cell proliferation experiment showed that mezlocillin at 20 μg/mL had the most significant effect on the proliferation of osteoblasts.Conclusion:The candidate OP therapeutic compound, mezlocillin, was screened from the L1000 data set with good ADMET characteristics and bone cell proliferation promoting activity.
|
|
Received: 17 May 2021
|
|
|
|
| ［1］Brum AM, van de Peppel J, van der Leije CS, et al. Connectivity Mapbased discovery of parbendazole reveals targetable human osteogenic pathway［J］. Proc Natl Acad Sci U S A, 2015, 112（41）:12711-12716.
［2］Brum AM, Van de PJ, Nguyen L, et al. Using the Connectivity Map to discover compounds influencing human osteoblast differentiation［J］.J Cell Physiol, 2018, 233（6）:4895-4906.
［3］严伟, 王中汉, 刘贺. 骨重建失衡导致骨质疏松发生的作用机制及其药物治疗策略［J］.中国组织工程研究, 2020, 24（30）:4866-4874.
［4］Subramanian A, Narayan R, Corsello SM, et al. A next generation connectivity map: L1000 platform and the first 1000000 profiles［J］. Cell, 2017, 171（6）: 1437-1452.
［5］Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologistoriented resource for the analysis of systemslevel datasets［J］. Nat Commun, 2019,10（1）:1523.
［6］Wang Y, Zhang S, Li F,et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics［J］. Nucleic Acids Res, 2020, 48（D1）: D1031-D1041.
［7］孙静. 蛇床子素促成骨作用及代谢多态性研究［D］.天津:天津医科大学,2019.
［8］梁鹏晨,周紫艳,孙苗苗,等.鄂版肺炎1号方治疗新型冠状病毒肺炎的生物信息学研究［J］.上海中医药杂志,2020,54（9）:1-8,19.
［9］Pires DE, Blundell TL, Ascher DB. pkCSM: predicting smallmolecule pharmacokinetic and toxicity properties using graphbased signatures［J］. J Med Chem, 2015,58（9）:4066-4072.
［10］谢梅青,谢小倩.绝经激素治疗的获益与风险［J］.协和医学杂志, 2021,12（2）:151-156.
［11］叶丹.骨质疏松药物治疗的研究进展［J］.牡丹江医学院学报,2021,42（1）:148-151.
［12］李朝阳,吴铁,林柏云,等.己烯雌酚对去卵巢大鼠骨代谢影响的定量研究［J］.中国药理学通报,1997,13（1）:39-41.
［13］许碧连,吴铁,崔燎,等.己烯雌酚对去卵巢大鼠不同部位骨骼的影响［J］.中国老年学杂志,2004,12（24）:1173-1176.
［14］Han HW, Hahn S, Jeong HY, et al. LINCS L1000 datasetbased repositioning of CGP60474 as a highly potent antiendotoxemic agent［J］. Sci Rep, 2018, 8（1）:14969.
［15］Sendama W. L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARSCoV2 antiviral therapies［J］. Comput Struct Biotechnol J, 2020, 18: 3947-3949.
［16］Zhang L, Wang Z, Liu R, et al. Connectivity mapping identifies BI2536 as a potential drug to treat diabetic kidney disease［J］. Diabetes, 2021,70（2）:589-602.
|
|
|
|
